27890602|t|The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine -induced antinociception, and attenuated heroin seeking behavior in mice
27890602|a|Although opioids are highly efficacious analgesics, their abuse potential and other untoward side effects diminish their therapeutic utility. The addition of non-opioid analgesics offers a promising strategy to reduce required antinociceptive opioid doses that concomitantly reduce opioid-related side effects. Inhibitors of the primary endocannabinoid catabolic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) show opioid - sparing effects in preclinical models of pain. As simultaneous inhibition of these enzymes elicits enhanced antinociceptive effects compared with single enzyme inhibition, the present study tested whether the dual FAAH - MAGL inhibitor SA-57 [4-[2-(4-chlorophenyl)ethyl]-1-piperidinecarboxylic acid 2-(methylamino)-2-oxoethyl ester] produces morphine -sparing antinociceptive effects, without major side effects associated with either drug class. SA-57 dose -dependently reversed mechanical allodynia in the constriction injury (CCI) of the sciatic nerve model of neuropathic pain and carrageenan inflammatory pain model. As previously reported, SA-57 was considerably more potent in elevating anandamide (AEA) than 2-arachidonyl glycerol (2-AG) in brain. Its anti-allodynic effects required cannabinoid (CB)1 and CB2 receptors; however, only CB2 receptors were necessary for the anti-edematous effects in the carrageenan assay. Although high doses of SA-57 alone were required to produce antinociception, low doses of this compound, which elevated AEA and did not affect 2-AG brain levels, augmented the antinociceptive effects of morphine, but lacked cannabimimetic side effects. Because of the high abuse liability of opioids and implication of the endocannabinoid system in the reinforcing effects of opioids, the final experiment tested whether SA-57 would alter heroin seeking behavior. Strikingly, SA-57 reduced heroin - reinforced nose poke behavior and the progressive ratio break point for heroin. In conclusion, the results of the present study suggest that inhibition of endocannabinoid degradative enzymes represents a promising therapeutic approach to decrease effective doses of opioids needed for clinical pain control, and may also possess therapeutic potential to reduce opioid abuse.
27890602	4	19	endocannabinoid	T109,T123	C1172779
27890602	20	30	hydrolysis	T070	C0020291
27890602	31	40	inhibitor	T080	C1999216
27890602	41	46	SA-57	T109,T121	C4310529
27890602	58	73	antinociceptive	T033	C1866932
27890602	74	81	effects	T080	C1280500
27890602	93	101	morphine	T109,T121	C0026549
27890602	111	126	antinociception	T033	C1866932
27890602	143	149	heroin	T109,T121,T131	C0011892
27890602	150	166	seeking behavior	T033	C0694536
27890602	170	174	mice	T015	C0025929
27890602	184	191	opioids	T109,T121,T131	C0242402
27890602	215	225	analgesics	T109,T121,T131	C0002771
27890602	233	248	abuse potential	T048	C0013146
27890602	259	280	untoward side effects	T046	C0879626
27890602	296	307	therapeutic	T169	C0302350
27890602	308	315	utility	T169	C0457083
27890602	333	354	non-opioid analgesics	T121	C0242937
27890602	402	417	antinociceptive	T033	C1866932
27890602	418	424	opioid	T109,T121,T131	C0242402
27890602	425	430	doses	T081	C0178602
27890602	457	484	opioid-related side effects	T048	C0027412
27890602	486	496	Inhibitors	T120	C0243077
27890602	512	527	endocannabinoid	T109,T123	C1172779
27890602	528	537	catabolic	T039	C1516314
27890602	538	545	enzymes	T116,T126	C0014442
27890602	546	572	fatty acid amide hydrolase	T116,T126	C0531004
27890602	574	578	FAAH	T116,T126	C0531004
27890602	584	607	monoacylglycerol lipase	T116,T126	C0026452
27890602	609	613	MAGL	T116,T126	C0026452
27890602	620	626	opioid	T109,T121,T131	C0242402
27890602	629	644	sparing effects	T046	C0879626
27890602	648	666	preclinical models	T170	C1514292
27890602	670	674	pain	T184	C0030193
27890602	679	691	simultaneous	T079	C0521115
27890602	692	702	inhibition	T052	C3463820
27890602	712	719	enzymes	T116,T126	C0014442
27890602	728	736	enhanced	T052	C2349975
27890602	737	752	antinociceptive	T033	C1866932
27890602	753	760	effects	T080	C1280500
27890602	782	799	enzyme inhibition	T039	C1524081
27890602	843	847	FAAH	T116,T126	C0531004
27890602	850	854	MAGL	T116,T126	C0026452
27890602	855	864	inhibitor	T121	C0014432
27890602	865	870	SA-57	T109,T121	C4310529
27890602	872	960	4-[2-(4-chlorophenyl)ethyl]-1-piperidinecarboxylic acid 2-(methylamino)-2-oxoethyl ester	T109,T121	C4310529
27890602	971	979	morphine	T109,T121	C0026549
27890602	989	1004	antinociceptive	T033	C1866932
27890602	1005	1012	effects	T080	C1280500
27890602	1028	1040	side effects	T046	C0879626
27890602	1064	1074	drug class	T121	C1254351
27890602	1076	1081	SA-57	T109,T121	C4310529
27890602	1082	1086	dose	T081	C0178602
27890602	1109	1129	mechanical allodynia	T184	C2936719
27890602	1137	1156	constriction injury	T037	C0332680
27890602	1158	1161	CCI	T037	C0332680
27890602	1170	1183	sciatic nerve	T023	C0036394
27890602	1193	1209	neuropathic pain	T033	C3714625
27890602	1214	1225	carrageenan	T109,T121,T123	C0007289
27890602	1226	1243	inflammatory pain	T184	C0234251
27890602	1275	1280	SA-57	T109,T121	C4310529
27890602	1323	1333	anandamide	T109,T123	C0211726
27890602	1335	1338	AEA	T109,T123	C0211726
27890602	1345	1367	2-arachidonyl glycerol	T109,T121	C0299477
27890602	1369	1373	2-AG	T109,T121	C0299477
27890602	1378	1383	brain	T023	C0006104
27890602	1389	1411	anti-allodynic effects	T033	C0243095
27890602	1421	1438	cannabinoid (CB)1	T116,T192	C0378126
27890602	1443	1456	CB2 receptors	T116,T192	C0208757
27890602	1472	1485	CB2 receptors	T116,T192	C0208757
27890602	1509	1531	anti-edematous effects	T033	C0243095
27890602	1539	1550	carrageenan	T109,T121,T123	C0007289
27890602	1551	1556	assay	T059	C1510438
27890602	1567	1577	high doses	T081	C0444956
27890602	1581	1586	SA-57	T109,T121	C4310529
27890602	1618	1633	antinociception	T033	C1866932
27890602	1635	1644	low doses	T081	C0445550
27890602	1653	1661	compound	T109,T121	C4310529
27890602	1669	1677	elevated	T080	C3163633
27890602	1678	1681	AEA	T109,T123	C0211726
27890602	1701	1705	2-AG	T109,T121	C0299477
27890602	1706	1711	brain	T023	C0006104
27890602	1712	1718	levels	T080	C0441889
27890602	1720	1729	augmented	T081	C0205217
27890602	1734	1749	antinociceptive	T033	C1866932
27890602	1750	1757	effects	T080	C1280500
27890602	1761	1769	morphine	T109,T121	C0026549
27890602	1782	1796	cannabimimetic	T073	C1136386
27890602	1797	1809	side effects	T046	C0879626
27890602	1831	1846	abuse liability	T080	C0237444
27890602	1850	1857	opioids	T109,T121,T131	C0242402
27890602	1881	1903	endocannabinoid system	T044	C3156138
27890602	1911	1930	reinforcing effects	T080	C1280500
27890602	1934	1941	opioids	T109,T121,T131	C0242402
27890602	1953	1963	experiment	T062	C0681814
27890602	1979	1984	SA-57	T109,T121	C4310529
27890602	1997	2003	heroin	T109,T121,T131	C0011892
27890602	2004	2020	seeking behavior	T033	C0694536
27890602	2034	2039	SA-57	T109,T121	C4310529
27890602	2048	2054	heroin	T109,T121,T131	C0011892
27890602	2057	2086	reinforced nose poke behavior	T053	C0004927
27890602	2129	2135	heroin	T109,T121,T131	C0011892
27890602	2179	2184	study	T062	C0008972
27890602	2198	2208	inhibition	T039	C1524081
27890602	2212	2227	endocannabinoid	T109,T123	C1172779
27890602	2228	2239	degradative	T040	C0699900
27890602	2240	2247	enzymes	T116,T126	C0014442
27890602	2271	2291	therapeutic approach	T061	C0087111
27890602	2304	2313	effective	T080	C1280519
27890602	2314	2319	doses	T081	C0178602
27890602	2323	2330	opioids	T109,T121,T131	C0242402
27890602	2342	2350	clinical	T080	C0205210
27890602	2351	2363	pain control	T061	C1304888
27890602	2386	2397	therapeutic	T169	C0302350
27890602	2398	2407	potential	T080	C3245505
27890602	2418	2430	opioid abuse	T048	C0029095